Skip to main content
LOGIN
Solutions
Solutions
Solutions for Integrated Delivery Networks
Solutions for Community Cancer Centers
Solutions for Academic Institutions and NCI-Designated Cancer Centers
Solutions for Life Science
Resources
Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Schedule A Demo
Solutions
Next Level Multidisciplinary Cancer Care Solutions for Cancer Centers, Oncology Practices and Life Science Organizations
Academic and NCI
Cancer Center Solutions
Leading institutions rely on OncoLens to drive clinical trial research, multidisciplinary care, and affiliate network engagement.
Community Cancer
Center Solutions
100+ community cancer centers and oncology practices use OncoLens to improve patient access to next level multidisciplinary care, accreditations, and quality improvement.
Integrated Delivery Network (IDN) Solutions
The OncoLens platform drives standardization and provider engagement across the entire network.
Life Sciences Solutions
Life Sciences Organizations work with OncoLens to collaborate with its oncology network, the largest in the United States.
Next Level
Multidisciplinary Cancer Care
Explore the OncoLens Platform
Schedule a Demo
Resources
Project ECHO® Learning Series
Evolving Role of Bispecific Antibodies as Cancer Therapy
Join ACCC, Physicians' Education Resource (PER), and Pharmacy Times Continuing Education (PTCE) for a five-part complimentary tele-mentoring series on the optimal use of bispecific antibodies as cancer immunotherapies.
LEARN MORE and REGISTER
OncoLens Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.
More than 10% of all cancer centers in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.
2,000,000+
Patients under Care in 200+ Cancer Centers
143,000+
Multidisciplinary Case Discussions
24,000+
Comprehensive Tumor Conferences
About OncoLens
About Us
Meet Our Leadership Team
Awards
Meet Our Board of Directors
Contact Us
Careers
Schedule a Demo
Careers
Solutions
Next Level Multidisciplinary Cancer Care Solutions for Cancer Centers, Oncology Practices and Life Science Organizations
Academic and NCI
Cancer Center Solutions
Leading institutions rely on OncoLens to drive clinical trial research, multidisciplinary care, and affiliate network engagement.
Community Cancer
Center Solutions
100+ community cancer centers and oncology practices use OncoLens to improve patient access to next level multidisciplinary care, accreditations, and quality improvement.
Integrated Delivery Network (IDN) Solutions
The OncoLens platform drives standardization and provider engagement across the entire network.
Life Sciences Solutions
Life Sciences Organizations work with OncoLens to collaborate with its oncology network, the largest in the United States.
Next Level
Multidisciplinary Cancer Care
Explore the OncoLens Platform
Resources
Project ECHO® Learning Series
Expert-led telementoring sessions focused on irAE monitoring and management strategies for approved cancer immunotherapies.
LEARN MORE and REGISTER
Hosted by ACCC and Boston University. Sponsored by Bristol Myers Squibb.
Powered by OncoLens.
OncoLens Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.
More than 10% of all cancer centers in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.
2,000,000+
Patients under Care in 200+ Cancer Centers
118,000+
Multidisciplinary Case Discussions
19,000+
Comprehensive Tumor Conferences
About OncoLens
About Us
Meet Our Leadership Team
Awards
Meet Our Board of Directors
Contact Us
Careers
Schedule A Demo
SCHEDULE A DEMO
LOGIN
Education
Combining 3D Cell Culture Chemosensitivity Results and NGS Profiles to Maximize Outcomes in Glioblastoma (Session 4 of 6)
Topics —
high grade glioma
,
Kiyatec
Jan 24, 2024
|
Education
Optimizing the Management of Newly Diagnosed Ovarian Cancer Including Maintenance (Session 3 of 3)
Topics —
ovarian cancer
,
UK Markey
Oct 9, 2023
|
Education
Lung Cancer Screening and Identification of Lung Cancer Patients at All Stages (Session 2 of 3)
Topics —
lung cancer
,
UK Markey
Jul 11, 2023
|
Education
Personalizing Treatment in High Grade Glioma using 3D Ex Vivo Technology (Session 3 of 6)
Topics —
high grade glioma
,
Kiyatec
Jun 12, 2023
|
Education
Expert Insights into Management of Advanced Triple Negative Breast Cancer (Session 1 of 3)
Topics —
breast cancer
,
UK Markey
Jun 7, 2023
|
Education
Using Live Patient-specific Tumor Tissue to Predict Therapeutic Response(s) in HGG Patients Before Treatment Initiation (Session 2 of 6)
Topics —
high grade glioma
,
Kiyatec
May 30, 2023
|
Education
Functional Precision Oncology: Revolutionizing the Future of Cancer Care by Predicting Individual Patient Response(s) to Oncology Drugs (Session 1 of 6)
Topics —
high grade glioma
,
Kiyatec
Apr 25, 2023
|
Education
Building and Engaging Affiliate Cancer Care Networks Webinar
Topics —
cancer care affiliate networks
Mar 22, 2023
|
Education
Quality Improvement Program Webinar—Breast and Ovarian Cancer Biomarker Testing
Topics —
breast cancer
,
ovarian cancer
,
QIP
Mar 15, 2022
|
Education
Quality Improvement Program Webinar—NSCLC Biomarker Testing
Topics —
NSCLC
,
QIP
Mar 8, 2022
|
Education
Lung Cancer Patient with 3 EGFR Mutations
Topics —
EGFR
,
lung cancer
Apr 1, 2021
|
Education
Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation
Topics —
BRCA
,
ovarian cancer
Apr 1, 2021
|
Education
Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations
Topics —
BRCA
,
EGFR
,
lung cancer
,
ovarian cancer
Apr 1, 2021
|
Education
NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients
Topics —
EGFR
,
Exon 19 Deletion
,
lung cancer
,
NSCLC
Mar 1, 2021
|
Education
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Topics —
EGFR
,
Exon 19 Deletion
,
lung cancer
Mar 1, 2021
|
Education
NSCLC Patient and Adjuvant Chemotherapy
Topics —
EGFR
,
lung cancer
,
NSCLC
Mar 1, 2021
|
Education
Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results
Topics —
lung cancer
,
NSCLC
Feb 1, 2021
|
Education
Patient with NSCLC Who Recurred within a Year
Topics —
EGFR
,
lung cancer
,
NSCLC
Feb 1, 2021
|
Education
Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion
Topics —
EGFR
,
Exon 19 Deletion
,
lung cancer
,
NSCLC
Feb 1, 2021
|
Education
Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy
Topics —
EGFR
,
Exon 19 Deletion
,
lung cancer
,
NSCLC
Feb 1, 2021
|
Education
MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations
Topics —
ATM
,
gastric cancer
,
KIT Exon 11
Dec 1, 2020
|
Education
Blog
Case Studies
CME
Education
News and Events